| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1026018402 |
| P356 | DOI | 10.2165/00019053-200826100-00002 |
| P698 | PubMed publication ID | 18793029 |
| P50 | author | Scott Metcalfe | Q108658612 |
| P2093 | author name string | Jackie Evans | |
| Peter Alsop | |||
| P2860 | cites work | Pharmaceutical industry sponsorship and research outcome and quality: systematic review | Q24673248 |
| A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth | Q28283339 | ||
| Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 | ||
| Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. | Q33979412 | ||
| Towards the optimal use of inhaled corticosteroid therapy in adult asthma | Q34308533 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration | Q34571631 | ||
| Off-label use of medicines: consensus recommendations for evaluating appropriateness | Q34583055 | ||
| PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer | Q34641398 | ||
| Ethnicity, equity, and quality: lessons from New Zealand | Q35827424 | ||
| Users' guide to detecting misleading claims in clinical research reports | Q35940538 | ||
| Value based pricing for NHS drugs: an opportunity not to be missed? | Q36420631 | ||
| Leaping to conclusions | Q37176980 | ||
| Medicines funding: Value for money is nothing new. | Q42414503 | ||
| Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial | Q42684584 | ||
| Non-drug industry funded research | Q42919459 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Addressing uncertainties about the effects of treatments offered to NHS patients: whose responsibility? | Q55276183 | ||
| The value meal: how to save $1,700 per month or more on lapatinib | Q80628256 | ||
| Trastuzumab in early-stage breast cancer: the question of treatment timing | Q81967926 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 811-814 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Funding a clinical trial: the perspective of a medicines funder | |
| P478 | volume | 26 |
Search more.